Clinical predictive model for identifying high-risk factors in pleurisy tuberculoma patients.

IF 3.5 3区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS
Weiwei Gao, Chen Yang, Tianzhen Wang, Yicheng Guo, Guangchuan Dai, Weiyi Hu, Shanshan Chen, Xiaoli Tang, Chunyang Yin, Cheng Chen, Yi Zeng
{"title":"Clinical predictive model for identifying high-risk factors in pleurisy tuberculoma patients.","authors":"Weiwei Gao, Chen Yang, Tianzhen Wang, Yicheng Guo, Guangchuan Dai, Weiyi Hu, Shanshan Chen, Xiaoli Tang, Chunyang Yin, Cheng Chen, Yi Zeng","doi":"10.1016/j.rmed.2025.108039","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Pleurisy tuberculoma (PTM) is a neoplastic lesion that primarily affects the pleural wall or internal organs. The majority of PTM cases are observed during the treatment of tuberculous pleural effusion(TPE), and although the precise pathogenesis remains unclear, there is a significant association between these two conditions. To identify high-risk factors for the development of PTM, we developed a clinical predictive model aimed at providing more insightful information for the development of PTM.</p><p><strong>Methods: </strong>A retrospective study was conducted on patients diagnosed with PTM or TPE who were treated at Nanjing Chest Hospital and the Second Hospital of Nanjing from March 2013 to April 2024. Predictors were identified using logistic regression, LASSO regression, and optimal subset regression. The performance of all models was evaluated using receiver operating characteristic (ROC) curves, calibration curves, decision curve analysis (DCA), and clinical impact curves to establish the final clinical predictive model. Internal and external validation was performed to assess the model's performance.</p><p><strong>Results: </strong>The final predictive model included two key risk factors associated with the development of PTM: Ki-67<sup>+</sup>CD4<sup>+</sup>T cells and Ki-67<sup>+</sup>CD8<sup>+</sup>T cells. The final model demonstrated good clinical net benefit and predictive validity, high predictive accuracy (Brier score: 0.033, 95%CI: 0.011-0.054), and strong differentiation (AUC: 0.987, 95%CI: 0.969-1.000). The model's robust performance was demonstrated by both internal and external verification.</p><p><strong>Conclusions: </strong>The predictive model utilizing Ki-67+CD4+T cells and Ki-67+CD8+T cells can assist clinicians in making early predictions of PTM.</p>","PeriodicalId":21057,"journal":{"name":"Respiratory medicine","volume":" ","pages":"108039"},"PeriodicalIF":3.5000,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Respiratory medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.rmed.2025.108039","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Pleurisy tuberculoma (PTM) is a neoplastic lesion that primarily affects the pleural wall or internal organs. The majority of PTM cases are observed during the treatment of tuberculous pleural effusion(TPE), and although the precise pathogenesis remains unclear, there is a significant association between these two conditions. To identify high-risk factors for the development of PTM, we developed a clinical predictive model aimed at providing more insightful information for the development of PTM.

Methods: A retrospective study was conducted on patients diagnosed with PTM or TPE who were treated at Nanjing Chest Hospital and the Second Hospital of Nanjing from March 2013 to April 2024. Predictors were identified using logistic regression, LASSO regression, and optimal subset regression. The performance of all models was evaluated using receiver operating characteristic (ROC) curves, calibration curves, decision curve analysis (DCA), and clinical impact curves to establish the final clinical predictive model. Internal and external validation was performed to assess the model's performance.

Results: The final predictive model included two key risk factors associated with the development of PTM: Ki-67+CD4+T cells and Ki-67+CD8+T cells. The final model demonstrated good clinical net benefit and predictive validity, high predictive accuracy (Brier score: 0.033, 95%CI: 0.011-0.054), and strong differentiation (AUC: 0.987, 95%CI: 0.969-1.000). The model's robust performance was demonstrated by both internal and external verification.

Conclusions: The predictive model utilizing Ki-67+CD4+T cells and Ki-67+CD8+T cells can assist clinicians in making early predictions of PTM.

导言:胸膜炎结核瘤(PTM)是一种主要影响胸膜壁或内脏器官的肿瘤性病变。大多数 PTM 病例是在结核性胸腔积液(TPE)的治疗过程中发现的,虽然确切的发病机制仍不清楚,但这两种病症之间存在显著关联。为了确定发生 PTM 的高危因素,我们建立了一个临床预测模型,旨在为 PTM 的发生提供更有洞察力的信息:方法:我们对2013年3月至2024年4月期间在南京市胸科医院和南京市第二医院接受治疗的PTM或TPE患者进行了回顾性研究。使用逻辑回归、LASSO 回归和最优子集回归确定了预测因子。使用接收者操作特征曲线(ROC)、校准曲线、决策曲线分析(DCA)和临床影响曲线对所有模型的性能进行评估,以建立最终的临床预测模型。为了评估模型的性能,还进行了内部和外部验证:最终预测模型包括两个与 PTM 发展相关的关键风险因素:Ki-67+CD4+T 细胞和 Ki-67+CD8+T 细胞。最终模型显示出良好的临床净效益和预测有效性、较高的预测准确性(Brier 评分:0.033,95%CI:0.011-0.054)和较强的区分度(AUC:0.987,95%CI:0.969-1.000)。该模型的稳健性能通过了内部和外部验证:结论:利用 Ki-67+CD4+T 细胞和 Ki-67+CD8+T 细胞的预测模型可以帮助临床医生对 PTM 进行早期预测。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Respiratory medicine
Respiratory medicine 医学-呼吸系统
CiteScore
7.50
自引率
0.00%
发文量
199
审稿时长
38 days
期刊介绍: Respiratory Medicine is an internationally-renowned journal devoted to the rapid publication of clinically-relevant respiratory medicine research. It combines cutting-edge original research with state-of-the-art reviews dealing with all aspects of respiratory diseases and therapeutic interventions. Topics include adult and paediatric medicine, epidemiology, immunology and cell biology, physiology, occupational disorders, and the role of allergens and pollutants. Respiratory Medicine is increasingly the journal of choice for publication of phased trial work, commenting on effectiveness, dosage and methods of action.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信